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Administration of L-arginine has been shown to control isch-
emic  injury  by  producing  nitric  oxide  which  dilates  the  vessels 
and thus maintains proper blood flow to the myocardium. In the 
present study attempt has been made to determine whether oral 
administration of L-arginine has any effect on oxidant/antioxidant 
homeostasis in ischemic myocardial patients [represented by the 
patients  of  acute  angina  (AA)  and  acute  myocardial  infarction 
(MI)].  L-arginine  has  antioxidant  and  antiapoptotic  properties, 
decreases endothelin-1 expression and improves endothelial func-
tion, thereby controlling oxidative injury caused during myocardial 
ischemic  syndrome.  Effect  of  L-arginine  administration  on  the 
status of free radical scavenging enzymes, pro-oxidant enzyme and 
antioxidants viz. total thiols, carbonyl content and plasma ascorbic 
acid levels in the patients has been evaluated. We have observed that 
L-arginine administration (three grams per day for 15 days) resulted 
in increased activity of free radical scavenging enzyme superoxide 
dismutase (SOD) and increase in the levels of total thiols (T-SH) 
and ascorbic acid with concomitant decrease in lipid per-oxidation, 
carbonyl content, serum cholesterol and the activity of proxidant 
enzyme, xanthine oxidase (XO). These findings suggest that the 
supplementation of L-arginine along with regular therapy may be 
beneficial to the patients of ischemic myocardial syndromes.
Introduction
Myocardial ischemia can result from a variety of pathological and 
physiological disorders. Whatever the cause of ischemia, the conse-
quence is always decreased oxygen availability to the myocardium. 
Insufficient oxygen supply fails to support oxidative phosphoryla-
tion. Within few minutes of ischemia, to meet the energy demand, 
glycolytic pathway is greatly stimulated with resultant accumula-
tion of lactic acid resulting in acidosis. Anaerobic production of 
ATP in this situation is insufficient to meet the energy demand 
of the tissues. With continuing ischemia the tissue levels of ATP 
fall and this initiates a series of events, especially oxidative stress 
conditions, which are deleterious to the endothelial cells. Oxidative 
stress,  associated  with  increased  formation  of  reactive  oxygen 
species  (ROS),  modifies  phospholipids  and  proteins  leading  to 
lipid per-oxidation and oxidation of thiol groups. These changes 
are considered to alter the membrane permeability and configura-
tion.1,2 Oxidative stress may result in cellular defects including 
a depression in the sarcolemmal (SL) Ca2+ pump, ATPase and 
Na+-K+ ATPase activities. These changes lead to decreased Ca2+ 
efflux and increased Ca2+ influx3 and thus inhibit Ca2+ sequestra-
tion from the cytoplasm in the cardiomyocytes.4,5 The oxidative 
stress induced changes in sarcoplasmic reticulum (SR) Ca2+ and 
SL Na+-K+ pumps are not limited only to cardiomyocytes but have 
also been observed in the coronary artery smooth muscle cells.6 
The depression in Ca2+ regulatory mechanism by ROS ultimately 
results in intracellular Ca2+ overload and cell death. On the other 
hand, an increase in Ca2+ during ischemia induces conversion of 
xanthine dehydrogenase to xanthine oxidase, by selective prote-
olysis,  that  generates  more  of  super  oxide  radicals.7 The  super 
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oxide radicals, though less toxic by itself, triggers the formation 
of other reactive oxygen species. These include OH., H2O2 and 
HOCl-. The hydroxyl radicals, in particular, interact with lipids, 
proteins  and  nucleic  acids  resulting  in  the  loss  of  membrane 
integrity, structural and functional changes in enzymes, proteins 
and genetic material.8 These deleterious effects result in the loss 
of heart contractile function and severe myocardial cell damage. 
To counter the damaging effects of ROS, body has evolved certain 
defense mechanisms to deactivate/destroy them before they can 
cause damage. The oxidative damage will occur only in situations 
when the defense mechanisms are deficient, made less active or 
production of ROS exceeds the capabilities of defense mechanism 
or a combination of all these. The first line of defense in the body 
are enzymatic free radical scavengers such as superoxide dismutase 
(SOD),  catalase,  glutathione  peroxidase  (GPx)  and  glutathione 
reductase (GR). SOD is considered to be the first line of defense 
against oxidative insult, as this enzyme efficiently converts oxygen 
derived  free  radical  to  hydrogen  peroxide.  Hydrogen  peroxide 
is more toxic than oxygen derived free radicals and is capable of 
producing most toxic OHo radical. It has, therefore, to be removed 
very efficiently. Catalase is the highly reactive enzyme in most of 
the tissues that converts toxic H2O2 to water. Another enzyme 
that  removes  H2O2  is  glutathione  peroxidase.  This  enzyme, 
almost equally efficient as catalase, removes H2O2 at the expense 
of oxidation of glutathione. Oxidized glutathione is reduced back 
by glutathione peroxidase. In fact catalase and glutathione peroxi-
dase cooperate in removing H2O2 in many tissues. For example, 
mammalian  red  blood  cells  (RBCs)  have  both  these  enzymes. 
The normal low rate of production of H2O2 by hemoglobin and 
SOD seems mainly dealt with glutathione peroxidase. However, 
catalase also contributes to removal of H2O2 if it’s concentration is 
raised.9 All these enzymes convert ROS to less toxic or non toxic 
products. The second line of defense to ROS is provided by anti-
oxidant compounds present in the body such as thiols, or taken 
from outside such as α-tocopherol, β-carotenoids, flavonoids and 
L-arginine. We have earlier shown that administration of vitamin 
C10,11 and vitamin E12,13 to the patients of ischemic myocardial 
syndromes lower lipid per-oxidation, increase the activities of free 
radical scavenging enzymes, which are decreased in these patients, 
and lower the activity of pro-oxidant enzyme which are elevated 
in the patients. Oxidized low density lipo-proteins are involved in 
the progression of atherosclerotic lesions14 which can be prevented 
by L-arginine administration. Moreover there are evidences that 
this amino acid preserves arterial vasodilation even in the presence 
of oxidative stress.15-17 A fine balance between ROS and various 
anti-oxidant mechanisms is crucial for avoiding myocardial injury.   
In  the  present  study  we  have  tried  to  evaluate  the  effect  of 
L-arginine  administration  on  certain  pro-oxidant  and  antioxi-
dant  parameters  in  myocardial  ischemic  syndromes  like  acute   
myocardial infarction and acute angina.
Results
Myocardial ischemic syndromes are almost invariably associated 
with alterations with oxidant and anti-oxidant parameters. Levels 
of SOD, an important enzymatic free radical scavenger and XO, 
the major source of free radical generation have been selected in the 
present study. MDA levels has been used as marker of free radical 
mediated  damage  along  with  carbonyl  content.  Levels  of  some 
non-enzymatic anti-oxidants namely total thiols and ascorbic acid 
and levels of serum cholesterol have been monitored before and 
after administration of L-arginine.
The  results  are  expressed  as  Mean  ±  SD.  One  way  analysis 
of  variance  (ANOVA)  followed  by  Newman-Keul’s  multiple 
comparison test is applied to assess the significance of the data.   
A p < 0.05 is considered to be statistically significant. Personal   
data of the subjects included in the study are reported in Table 1. 
Age  group,  blood  pressure  and  serum  cholesterol  levels  of  the 
subjects are reported in Table 2. Biochemical parameters inves-
tigated  are  presented  in Tables  3  and  4.  All  the  data  are  also 
represented graphically in Figures 1–7.
SOD. The specific activity of SOD in plasma of MI patients 
receiving L-arginine treatment along with regular anti-hyperten-
sive  therapy  (Group  2)  showed  significant  increase  (p  <  0.05) 
when compared to those receiving only anti-hypertensive therapy   
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Table 1    Personal profile of the subjects included in the 
study
1. No. of subjects
  *MI (without Arg/with Arg)  35/20
  *AA (without Arg/with Arg)  25/20
2. Sex  Males
3. Age  40–75 yrs
4. Duration of cardiac disease  Immediately after detection of 
prior to L-arginine therapy  the disease by the physician
5. Tobacco chewers  None
6. Smokers  None
7. Alcoholics  None
8. Diabetic/other known organic disease  None
9. Duration of L-arginine therapy (dose)  15 days (3 g/day)
10. Population  Indian
*No. of subjects; MI, Acute myocardial infarction; AA, Acute angina.
Table 2    Age and blood pressure of patients of acute 
myocardial infarction (MI) and acute angina 
(AA)
Groups  Age  Blood pressure  Serum cholesterol 
  (years)  (mm Hg)  (mg/dl)
Group (1)  60 ± 10  138 ± 10/77 ± 4  405.00 ± 76.70
Group (2)  60 ± 10  115 ± 5/80 ± 9  255.40 ± 41.53
Group (3)  55 ± 10  126 ± 14/81 ± 10  354.90 ± 71.09
Group (4)  55 ± 10  116 ± 5/77 ± 5  252.70 ± 42.51
Effect of L-arginine (Arg) administration on the levels of serum cholesterol in the patients of MI and AA 
are also reported. Serum cholesterol levels in patients was estimated by the method of Sperry and Webb. 
Values for cholesterol levels are presented as mean ± SD. Statistical significance of the groups has 
been determined by one way ANOVA followed by Newmann-Keul’s multiple comparison test. p values of 
serum cholesterol level are Group 1 vs. Group 2 p < 0.005; Group 3 vs. Group 4 p < 0.05.Effect of L-arginine in certain ischemic myocardial disorders
(Group 1). In acute angina patients L-arginine treatment though 
caused an increase in SOD activity but was statistically not signifi-
cant (p > 0.05, Group 4 vs. Group 3).
XO. Specific activity of XO was found to decrease significantly 
upon L-arginine treatment, both in the case of patients of MI   
and acute angina (Group 1 vs. 2 and Group 3 vs. 4; p < 0.005 and 
p < 0.05 respectively).
MDA. MDA levels in plasma were found to be significantly 
reduced (p < 0.05) when arginine was given in the case of MI 
patients (Table 2). There was decrease in the levels of MDA in 
the patients of acute angina also, but the decrease was statistically 
insignificant (p > 0.05).
Plasma ascorbic acid level. In both the patient groups, admin-
istration of arginine resulted in statistically significant increase in 
the levels of plasma ascorbic acid (Group 1 vs. Group 2, p < 0.05 
and Group 3 vs. 4, p < 0.05).
Total thiols. Total thiol levels also exhibited significant increase 
in both the cases of patients upon arginine incorporation in the 
therapy.
Carbonyl content in plasma protein. Incorporation of arginine 
in the therapy led to decrease in the levels of carbonyl content, 
in  case  of  MI  patients  the  decrease  was  statistically  significant   
(p < 0.05) whereas in the patients of angina it was not significant 
(p > 0.05).
Serum cholesterol. Incorporation of arginine was also effective 
in lowering the serum cholesterol levels in both groups of patients 
(Table 1) and this lowering was highly significant showing the   
p value of <0.005 in case of MI patients and <0.05 in the patients 
of angina.
Discussion
As reported in the results section, most of the oxidant-antiox-
idant parameters studied, showed a tendency to improve upon 
administration  of  L-arginine.  Most  of  the  xanthine  oxidizing 
activity present in healthy animal tissues occurs as a dehydrogenase 
enzyme that oxidizes hypoxanthine and/or xanthine to uric acid at 
the expense of NAD. During ischemia, insufficient oxygen supply 
fails to support oxidative phosphorylation, leading to lowering of 
tissue ATP levels and acidosis. ATP hydrolysis eventually leads to 
production  of  hypoxanthine  and  xanthine. Thus  there  is  accu-
mulation  of  substrates  of  xanthine  oxidase.18  As  mentioned  in 
the introduction section, levels of Ca+2 are also increased during 
ischemia. This increase in Ca+2 stimulates certain proteases that 
selectively  act  on  xanthine  dehydrogenase  to  convert  it  in  to 
xanthine  oxidase.19  Xanthine  oxidase  mediated  production  of 
OFRs plays major role in causing tissue damage observed in isch-
emia/reperfusion injury as evidenced by the fact that incorporation 
of specific inhibitors of xanthine oxidase, such as allopurinol and 
anti-oxidants, are capable to protect such damage in experimental 
models of myocardial injury.20-22 The series of events initiated by 
ischemia, lead to enhanced production of free radicals which is 
further increased upon reperfusion of ischemic myocardium.10,11
Oxy  free  radicals  are  removed  by  superoxide  dismutase  in 
healthy  organisms,  but  during  ischemia,  the  lowered  activity   
of  SOD  caused  by  inhibition  of  the  enzyme  by  excess  H2O2 
Table 3    Effect of L-arginine (Arg) administration on 
the activities of SOD and XO and MDA levels 
in patients of acute myocardial infarction (MI) 
and acute angina (AA)
Groups  SOD  XO  MDA 
  (unit/mg protein)  (unit/mg protein)  (nmole/ml)
Group 1  1.91 ± 0.79  0.94 ± 0.17  4.61 ± 1.27
Group 2  2.32 ± 0.68  0.68 ± 0.16  3.65 ± 1.24
Group 3  2.80 ± 0.71  0.82 ± 0.15  1.91 ± 0.75
Group 4  3.05 ± 0.77  0.65 ± 0.14  1.40 ± 0.48
SOD activity in patients was estimated by the method of Misra and Fridovich. Activity of XO was estimated 
by the method of Fried and Fried. Levels of MDA was determined by Ohkawa et al. Values are presented 
as mean ± SD. Statistical significance of the groups was determined by one way ANOVA followed by 
Newmann-Keul’s multiple comparison test. p values: Superoxide dismutase (SOD), Group 1 vs. Group 
2 p < 0.05; Group 3 vs. Group 4 p > 0.05. Xanthine oxidase (XO), Group 1 vs. Group 2 p < 0.005; 
Group 3 vs. Group 4 p < 0.05. Malondialdehyde (MDA), Group 1 vs. Group 2 p < 0. 05; Group 3 vs. 
Group 4 p > 0.05.
Table 4    Effect of L-arginine (Arg) administration on the 
levels of total thiols, ascorbic acid and  
carbonyl content in patients of acute  
myocardial infarction (MI) and acute angina 
(AA)
Groups  Total thiols  Ascorbate level  Carbonyl protein 
  (mmole/ml)  (mg/dl)  (μmole/ml)
Group 1  0.22 ± 0.067  0.26 ± 0.88  54.28 ± 22.92
Group 2  0.31 ± 0.068  0.37 ± 0.16  38.38 ± 17.48
Group 3  0.32 ± 0.041  0.39 ± 0.10  21.27 ± 11.57
Group 4  0.39 ± 0.072  0.49 ± 0.15  16.82 ± 7.11
Levels of total thiols in patients were estimated by the method of Hu. Ascorbic acid level was determined 
by the method of Omaye et al. Carbonyl content was determined by the method of Levini et al. Values 
are presented as mean ± SD. Statistical significance of the groups was determined by one way ANOVA 
followed by Newmann-Keul’s multiple comparison test. p values: Total thiols: Group 1 vs. Group 2 p < 
0.005; Group 3 vs. Group 4 p < 0.05. Ascorbic acid: Group 1 vs. Group 2 p < 0.05; Group 3 vs. Group 
4 p < 0.05. Carbonyl content: Group 1 vs. Group 2 p < 0. 05; Group 3 vs. Group 4 p > 0.05.
Figure 1. Effect of L-arginine (Arg) administration on the levels of Serum 
cholesterol in patients with acute myocardial infarction (MI) and acute 
angina (AA). Values are presented as mean with standard error bars. 
Statistical significance of the groups has been determined by one way 
ANOVA followed by Newmann-Keul’s multiple comparison test. p values 
of serum cholesterol levels are: MI vs. MI+ARG p < 0.005; A A vs. A 
A+ARG p < 0.05.
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production fails to cope with excessive production of free radicals 
and H2O2. This excess H2O2, besides inhibiting SOD, can cause 
degradation  of  heme  rings  of  hemoglobin  releasing  iron  which 
is capable of OH. production via Fenton reaction and lipid per-
oxidation.23 Lipid per-oxidation and free radical mediated damage 
during ischemia is indicated by increased MDA levels in patients 
suffering  from  myocardial  infarction  and  acute  angina  in  the 
present study. Total thiols can either chemically24 or enzymatically 
reduce dehydroascorbic acid (DHA) to ascorbate.25,26 The lower 
level of total thiols in patients may be responsible for the decreased 
conversion of DHA back to ascorbate. Ascorbic acid, an effec-
tive antioxidant is capable of completely protecting lipids against 
oxidative damage induced by peroxy radicals. It has chain breaking 
properties, reacts directly with superoxide ions, hydroxyl radicals 
and  singlet  oxygen  species  and  acts  to  generate  tocopherol.27 
During ischemia the lowered levels of total thiols may be respon-
sible for decreased conversion of DHA to ascorbate. This may be 
one of the reasons that we observed decreased levels of ascorbic 
acid in the patients. Decrease in ascorbate level fails to cope with 
per-oxidative damage of lipids and modification of phospholipids, 
thereby resulting in increased lipid per-oxidation. Decreased levels 
of total thiols also indicate the effect of oxidative damage of protein 
molecules due to excessive free radical generation during ischemia. 
Major parts of thiols are derived from proteins. Oxidative damage 
modifies  proteins  leading  to  oxidation  of  thiol  groups.28  The 
modifications in lipids and proteins caused due to decreased levels 
of ascorbic acid and thiols in patients alter membrane permeability 
and configuration in addition to producing functional modifica-
tion of various cellular proteins during ischemia. Excessive free 
radical  generation  during  ischemia  causes  the  inactivation  of 
enzymes and introduction of carbonyl groups into amino acid side 
chains of proteins. Increased carbonyl derivatives within proteins 
and enzyme inactivation suggest mixed—function oxidative modi-
fication.29
During ischemia, the myocardial tissue is exposed to an exac-
erbated injury caused by un-scavenged superoxide radicals, other 
free radicals, increased WBC, vasoconstriction and platelet adhe-
sion.30-32 Higher oxidant stress and diminished antioxidant status 
along with higher MDA levels constitutes the key factors in the 
progression of ischemic injury.
L-arginine serves as a precursor of nitric oxide (NO) synthesis. 
NO can reduce oxidative stress by inhibiting XO, scavenge super-
oxide radicals and terminate free radical chain reaction within the 
lipid membranes, thereby reducing inflammatory mediators.33,34 
Decreased ROS formation attenuates inhibition of SOD which 
is increased by L-arginine supplementation. In the present study, 
it was found that the level of ascorbic acid and total thiols also 
increased after L-arginine supplementation. Our present finding 
is  in  accordance  with.33  The  improved  levels  of  ascorbic  acid 
and total thiols cope with lipid and protein per-oxidation thus 
decreasing the damage of membrane and cellular proteins. By effi-
ciently reducing or eliminating these toxic metabolites L-arginine 
via NO retards the damaging effects of ischemic injury.34
L-arginine controls the modification of proteins due to excess 
carbonylation and that is why in our study, L-arginine was found to 
significantly decrease the plasma carbonyl contents in the patients. 
Figure 2. Effect of L-arginine (Arg) administration on superoxide dismutase 
(SOD) activity in patients with acute myocardial infarction (MI) and acute 
angina (AA). Values are presented as mean with standard error bars. 
Statistical significance of the groups has been determined by one way 
ANOVA followed by Newmann-Keul’s multiple comparison test. p values 
of  SOD  activity  are:  MI  vs.  MI+ARG  p  <  0.05;  A  A  vs.  AA  +ARG   
p > 0.05.
Figure 3. Effect of L-arginine (Arg) supplementation on xanthine oxidase 
(XO) activity in patients with acute myocardial infarction (MI) and acute 
angina (AA). Values are presented as mean with standard error bars. 
Statistical significance of the groups has been determined by one way 
ANOVA followed by Newmann-Keul’s multiple comparison test. p values of 
XO activity are: MI vs. MI+ARG p < 0.005; AA vs. AA+ARG p<0.05.
Figure 4. Effect of L-arginine (Arg) supplementation on the levels of malon-
dialdehyde (MDA) in patients with acute myocardial infarction (MI) and 
acute angina (AA). Values are presented as mean with standard error 
bars. Statistical significance of the groups has been determined by one 
way  ANOVA  followed  by  Newmann-Keul’s  multiple  comparison  test.   
p values of MDA levels are: MI vs. MI+ARG p < 0.05; AA vs. AA+ARG 
p > 0.05.
NO generated by L-arginine also inhibits vasoconstriction, platelet 
aggregation, expression of adhesion molecules,35 and chemotactic 
proteins.36 Another interesting finding of the present work is that 
L-arginine administration to the patients has serum cholesterol 
lowering effect, an observation reported by few earlier workers.37,38 Effect of L-arginine in certain ischemic myocardial disorders
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supplementation  to  these  patients.  Possible  pathway  presenting 
the  action  of  L-arginine  on  the  parameters  examined  in  the   
present study is provided in Figure 8.
L-arginine  supplementation,  along  with  standard  therapy  in 
the patients under present study, can maintain oxidant-antioxidant 
homeostasis and control the levels of lipid, cholesterol, ascorbic 
acid  and  protein  oxidation  in  patients  of  myocardial  ischemic 
syndromes.
Material and Methods
The study was cleared by the departmental ethical committee. 
Informed consent was obtained from individuals enrolled in the 
study. The study included 60 patients of the age group between 
40–75 suffering from myocardial infarction and acute angina.
The  patients  suffering  from  non  segment  elevation  myocar-
dial infarction before reperfusion were included in MI group of 
the study. These patients were receiving regular antihypertensive 
medication.
Patients with chest pain at rest and/or on effort, positive exer-
cise  tests  (chest  pain  associated  with  ST-segment  depression  of   
>0.1 mV) normal coronary arteriograms and no spasm of large 
epicardial  arteries  provoked  by  acetylcholine  were  included  in   
The  observed  lowering  of  serum  cholesterol  upon  L-arginine 
administration, has been ascribed to be mediated by NO derived 
from this amino acid.39 The adhesiveness of mononuclear cells 
is  increased  in  hyper-cholesterolemic  conditions.  The  increase 
in adhesiveness and cholesterol levels lead to atherosclerosis and 
myocardial  infarction  and  can  be  taken  care  of  by  L-arginine 
Figure 6. Effect of L-arginine (Arg) supplementation on the levels of ascorbic 
acid in patients with acute myocardial infarction (MI) and acute angina 
(AA). Values are presented as mean with standard error bars. Statistical 
significance of the groups has been determined by one way ANOVA fol-
lowed by Newmann-Keul’s multiple comparison test. p values of ascorbic 
acid levels are: MI vs. MI+ARG p < 0.05; AA vs. AA+ARG p < 0.05.
Figure 7. Effect of L-arginine (Arg) supplementation on the levels of car-
bonyl content in patients with acute myocardial infarction (MI) and acute 
angina (AA). Values are presented as means with standard error bars. 
Statistical significance of the groups has been determined by one way 
ANOVA followed by Newmann-Keul’s multiple comparison test. p values 
of  carbonyl  content  are:  MI  vs.  MI+ARG  p  <  0.05;  AA  vs.  AA+ARG   
p > 0.05.
Figure 8. Mechanism of action of L-arginine on the parameters examined 
in the present study. The action of L-arginine is shown to be mediated by 
nitric oxide (NO), which in turn, lowers (↓) the serum cholesterol level 
in patients, controls vasoconstriction and thus regulates their blood pres-
sure. Also, NO attenuates the activity of XO (↓) due to which the activity 
of SOD is elevated (↑). L-arginine is also shown to increase the levels of 
thiols and ascorbic acid (↑) and reduce MDA levels and carbonyl content 
in plasma (↓).
Figure 5. Effect of L-arginine (Arg) supplementation on the levels of total 
thiols in patients with acute myocardial infarction (MI) and acute angina 
(AA). Values are presented as mean with standard error bars. Statistical 
significance of the groups has been determined by one way ANOVA fol-
lowed by Newmann-Keul’s multiple comparison test. p values of total thiols 
levels are: MI vs. MI+ARG p < 0.005; AA vs. AA+ARG p < 0.05.Effect of L-arginine in certain ischemic myocardial disorders
236 Oxidative Medicine and Cellular Longevity 2009; Vol. 2 Issue 4
Estimation of ascorbic acid. Ascorbate level was estimated in 
the plasma by the method of Omaye, Turnbull and Sauberlich.42 
In the assay, 1.0 ml of plasma was precipitated with 1.0 ml of 10% 
(w/v) TCA (trichloro acetic acid). To 0.5 ml of the supernatant   
0.2 ml of DTC reagent (3.0 g dinitrophenylhydrazine, 0.4 g thio-
urea and 0.05 g CuSO4.5H2O in 100 ml 9 N H2SO4) was added 
and the mixture was incubated at 37°C for 3 h. 1.5 ml of 65% 
H2SO4 was then added to the reaction mixture and kept at room 
temperature for 30 min. Absorbance was measured at 520 nm. 
L-ascorbic acid in 5% TCA was used as reference.
Estimation of total thiols. Total thiols (T-SH) were estimated 
by the method of Hu43 using Ellman’s reagent. In final volume 
of  4.0  ml,  was  added  0.2  ml  plasma  and  0.6  ml  of  20  mM 
tris-HCl buffer pH 8.2, followed by addition of 0.04 ml of 10 
mM 5,5'-dithionitrobis 2-nitrobenzoic acid (DTNB) in absolute   
methanol  and  3.16  ml  of  absolute  methanol.  The  tubes  were 
capped and color was developed for 15 min at room tempera-
ture. The tubes were then centrifuged at 3,000 xg for 20 min. 
Supernatant was collected and absorbance measured at 412 nm.
Estimation of MDA. Levels of malondialdehyde (MDA) were 
measured as an index of oxidative stress by the method of Ohkawa, 
Ohishi and Yagi,44 using thiobarbituric acid (TBA) reagent. To 
0.2 ml plasma, in a Folin tube, was added 0.2 ml, 8.1% (w/v), 
sodium dodecylsulphate (SDS); 1.5 ml, 20% (v/v) acetic acid and 
1.1 ml of 0.8% (w/v) thiobarbituric acid to make up the volume 
to 3 ml. The tubes were heated in a water bath at 95°C for 1 h and 
cooled immediately under running tap water. To each tube, 1.0 ml 
water and 5.0 ml solution of butanol and pyridine (15:1 v/v) were 
added, vortexed and centrifuged at 800 xg for 20 min. The upper 
layer was aspirated out and color intensity measured at 532 nm.   
1,1,3.3-tetra ethoxy propane (TEP) was used as the reference.
Estimation  of  carbonyl  content  of  plasma  protein.  Protein 
oxidation was determined by protein carbonyl content in plasma 
by a modified method of Levini et al.45 From 0.5 ml of plasma, 
proteins were precipitated using 0.25 ml of 10% TCA. 0.75 ml 
of 10 mM DNPH (2,4-dinitrophenylhydrazine) in 2 M HCl was 
added to the precipitate and incubated at room temp for 30 min. 
The reaction mixture was re-centrifuged using the same amount of 
TCA as before. The precipitate, thus obtained, was washed twice 
with 1 ml ethanol/ethyl acetate (1:1 v/v) mixture. The precipitate 
was dissolved in 0.75 ml protein dissolving solution (2 g SDS 
and 50 mg EDTA in 100 ml 80 mM phosphate buffer, pH 8.0),   
incubated  for  10  min  at  room  temp. The  color  intensity  was 
measured at 370 nm against 2 M HCl. Carbonyl content was 
calculated using the molar extinction coefficient 22,000 M-1cm-1.
Estimation of serum cholesterol. Serum cholesterol was deter-
mined by the method of Sperry and Webb.46 To 0.04 ml serum, 
0.96 ml water was added to make up the volume to 1.0 ml. To this 
4.0 ml of color reagent (0.1 ml of 10.0 g FeCl3.6H2O pet 100 ml 
aldehyde free glacial acetic acid mixed with 15 ml 36 N H2SO4) 
and 6.0 ml acetic acid was added. The mixture was allowed to 
stand for 20 min. The color intensity was measured at 570 nm.
Protein estimation. Protein estimation has been carried out by 
the method of Lowry et al. using Folin phenol reagent.47 Bovine 
serum albumin was used as standard.
acute  angina  group.  All  these  patients  exhibited  evidence   
suggestive of myocardial ischemia. None of these patients had any 
ST-segment  abnormalities  in  their  resting  ECG’s. The  patients 
were receiving anti anginal medication.
Patients with previous cardiovascular or other organic diseases 
and those with severe trauma or surgery in preceding eight weeks 
were excluded from the study.
The patients were grouped in the following way:
Group (1): included 35 MI patients receiving regular therapy 
without L-arginine administration.
Group (2): included 20 MI patients assigned to regular therapy 
along with supplementation of oral dose of L-arginine (3 g/day) 
for 15 days.
Group  (3):  included  25  patients  of  acute  angina  receiving 
regular therapy without L-arginine supplementation.
Group  (4):  comprised  of  20  patients  of  acute  angina  with 
conventional therapy along with supplementation of L-arginine   
(3 g/day) for 15 days.
Regular treatments for both the groups (MI and acute angina) 
included  antihypertensive  drugs  like  nitroglycerine,  monotrate, 
metaprolal, aspirin and clopivas.
All the chemicals employed in the study were AnalaR grade 
of Qualigens, biochemicals employed were procured from Sigma 
Chemical Co., US.
Preparation  of  sample.  Venous  blood  (4.0  ml)  was  drawn 
aseptically from the subjects under study and transferred in poly-
propylene  tubes  containing  0.5  ml  3.8%  (w/v)  sodium  citrate,   
pH 7.2. The tubes were gently rotated to mix the contents and 
centrifuged  at  2,000  xg  for  20  min  at  4°C.  The  supernatant   
plasma was used for study.
Estimation  of  SOD.  SOD  was  assayed  in  plasma  by  the 
method  of  Misra  and  Fridovich.40  Three  ml  reaction  mixture 
consisted  of  1.5  ml  of  100  mM  carbonate  buffer,  pH  10.3;   
0.01 ml of 30 mM EDTA (ethylene diamine tetra acetic acid), 
suitable  aliquot  of  enzyme  preparation  and  water  to  make  up 
the volume to 2.94 ml. The reaction was started by addition of   
0.06  ml  of  15  mM  epinephrine.  Change  in  absorbance  was 
recorded  at  480  nm  for  one  min  at  15  sec  interval.  Control 
consisting of all the ingredients, except enzyme preparation, was 
run simultaneously.
One unit of enzyme activity has been defined to cause 50% 
inhibition of auto-oxidation of epinephrine present in the assay 
system by 1 ml enzyme preparation.
Estimation  of  XO.  XO  (Xanthine  oxidase)  was  assayed  in 
plasma by the method of Fried and Fried.41 The reaction mixture 
consisted of 0.9 ml of 0.1 M phosphate buffer pH 7.8; 0.75 ml 
10 mM EDTA; 0.15 ml 0.2 mg/ml phenazine methosulphate; 
0.45 ml 4 mg/ml nitroblue tetrazolium (NBT) salt; 0.5 ml 1 mM 
xanthine and water to make up the volume to 3.5 ml. The reac-
tion was started at 37°C by addition of 0.5 ml of 1 mM Xanthine 
for 1 min. Extinction coefficient of the reduced NBT at 540 nm 
is 7.2 cm/μmole.
One unit of enzyme activity has been defined as amount of 
enzyme that converts 1 μmole of xanthine to uric acid in one 
minute at specified conditions of assay.Effect of L-arginine in certain ischemic myocardial disorders
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